Energy News / Shareholders Foundation, Inc.

NASDAQ: HSDT Shareholder Notice: Investigation over Potential Wrongdoing at Helius Medical Technologies, Inc.

Via: ReleaseWire

Updated 11:30 AM CDT, Mon, April 22,2019

An investigation on behalf of investors in Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares over potential wrongdoing at Helius Medical Technologies, Inc. was announced and NASDAQ: HSDT stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWIRE) -- 04/22/2019 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Helius Medical Technologies, Inc.

Investors who purchased shares of Helius Medical Technologies, Inc. (NASDAQ: HSDT) and currently hold any of those NASDAQ: HSDT shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Helius Medical Technologies directors breached their fiduciary duties and caused damage to the company and its shareholders.

Newtown, PA based Helius Medical Technologies, Inc., a medical technology company, focuses on the development of products for the treatment of neurological symptoms caused by disease or trauma.

On January 22, 2019, an article was published stating that Helius Medical Technologies' phase III trial "missed its primary effectiveness endpoint" and that Helius "has redacted important trial info." The article further states that the founders "have a history of questionable marketing practices" and that the former CEO "is now a fugitive."

On April 10, 2019, Helius Medical Technologies' disclosed that the U.S. Food and Drug Administration ("FDA") had declined the Company's request for De Novo classification and clearance of its Portable Neuromodulation Stimulator device. The FDA stated that it lacked sufficient data to determine the relative contributions of the device and physical therapy in clinical studies
Shares of Helius Medical Technologies, Inc. (NASDAQ: HSDT) declined from $17.97 per share in October 2017 to as low as $1.77 per share on April 11, 2019.

Those who purchased shares of Helius Medical Technologies, Inc. (NASDAQ: HSDT) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit:
http://www.sbwire.com/press-releases/nasdaq-hsdt-shareholder-notice-investigation-over-potential-wrongdoing-at-helius-medical-technologies-inc-1200954.htm

Media Relations Contact
Michael Daniels
858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com